Nektar reports Q1 EPS (19c), consensus (19c)

Reports Q1 revenue $21.6M, consensus $15.34M. “In the Q1, we made significant progress with our highly promising immunology and inflammation pipeline,” said CEO Howard Robin. “REZPEG is advancing in the clinic in our Phase 2b study in patients with atopic dermatitis and in our Phase 2b study in patients with alopecia areata. Enrollment for both studies is on-track, and we expect to report topline data from these trials in the first half of 2025. Building out our Treg pipeline, our novel bivalent antibody targeting the TNFR2 receptor is progressing through IND-enabling studies to support entering the clinic next year.”